Search results
Mustang (MBIO) Soars 477% on Data From Rare Blood Cancer Study
Zacks via Yahoo Finance· 19 hours agoUpdated data from a clinical study shows that treatment with Mustang Bio's (MBIO) experimental cell...
Syndax reports encouraging results from AML treatment trials By Investing.com
Investing.com· 5 days agoSyndax Pharmaceuticals (NASDAQ: NASDAQ:SNDX), a clinical stage biopharmaceutical company, has...
Temporary housing for cancer patients opens next to Banner cancer center in Gilbert
The Arizona Republic· 7 days agoThe development, located on land adjacent to the cancer center, provides temporary housing for...
Mustang (MBIO) Soars 477% on Data From Rare Blood Cancer Study
Zacks· 1 day agoData from the study showed that treatment with MB-106 exhibited a favorable safety and efficacy profile in WM patients, all (n=10) of whom were heavily pre-treated/refractory ...
Immunotherapy to treat cancer gave rise to 2nd cancer in extremely rare case
Live Science via Yahoo News· 6 days agoKnown as chimeric antigen receptor (CAR) T-cell therapy, the treatment involves harvesting a...
EHA 2024: Brukinsa/Venclexta for CLL/SLL lacks control arm in SEQUOIA trial
Clinical Trials Arena via Yahoo Finance· 2 days agoCLL and SLL are among the most common haematological malignancies...) inhibitors and B cell lymphoma...
Immunotherapy to treat cancer gave rise to 2nd cancer in extremely rare case
LiveScience· 6 days agoKnown as chimeric antigen receptor (CAR) T-cell therapy, the treatment involves harvesting a...
For some Maine families, upcoming increase to TANF benefits could be a lifeline
Maine Morning Star via Yahoo News· 2 days agoFive years ago, McLaughlin’s son, Leon, was diagnosed with leukemia. He finished treatment two years...
Why Is Bio-Path (BPTH) Stock Up 20% Today?
InvestorPlace· 5 days agoBio-Path (NASDAQ:BPTH) stock is rising higher on Friday alongside data from the oncology-focused company’s Phase 2 clinical trial of prexigebersen....
Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's...
Benzinga· 2 days agoTakeda Pharmaceutical Co Ltd TAK announced topline data from its SKYLINE and SKYWAY Phase 3 studies of Soticlestat (TAK-935) for the treatment of Dravet syndrome (DS) and ...